2.2.0.25falsefalse1040 - Disclosure - ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSEtruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010 USD ($) USD ($) / shares $D2010http://www.sec.gov/CIK0000873364duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0ceph_AcquiredInProcessResearchAndDevelopmentExpenseDisclosureAbstractcephfalsenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalseACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE3false0us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> 4. ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE         In 2010, we recognized acquired in-process research and development expense of: <ul> <li style="list-style: none"> <dl compact="compact"> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$100.0 million in exchange for worldwide license rights to Mesoblast's proprietary technology platform.</dd></dl></li></ul>         In 2009, we recognized acquired in-process research and development expense of: <ul> <li style="list-style: none"> <dl compact="compact"> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$9.4 million in exchange for the elimination of the $15.0 million milestone and royalty payments associated with the celecoxib license agreement and Acusphere patent rights relating to its HDDS technology. See Note 2 herein; </dd> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$30.0 million in exchange for the exclusive, worldwide license rights to LUPUZORTM, acquired from ImmuPharma; </dd> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$0.8 million in exchange for exclusive sublicense rights to bendamustine hydrochloride in China and Hong Kong, acquired from SymBio; and </dd> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$6.0 million in exchange for license rights to certain of XOMA Ltd.'s proprietary antibody library materials. </dd></dl></li></ul>         In 2008, we recognized acquired in-process research and development expense of: <ul> <li style="list-style: none"> <dl compact="compact"> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$10.0 million related to our purchased of license rights for Acusphere's HDDS technology for use in oncology therapeutics; </dd> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$15.0 million related to LUPUZOR option rights; and </dd> <dt style="MARGIN-BOTTOM: -11pt; FONT-FAMILY: times"></dt> <dd style="FONT-FAMILY: times">$17.0 million in connection with the initial consolidation of Acusphere, a variable interest entity for which we are the primary beneficiary. </dd></dl></li></ul></td></tr></table> 4. ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE         In 2010, we recognized acquired in-process researchfalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescription, amount and terms involving research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 68 -Paragraph 14 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Audit and Accounting Guide (AAG) -Number AAG-FGC -Chapter 3 -Paragraph 56, 57 -IssueDate 2006-05-01 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 falsefalseACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE12ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSEUnKnownUnKnownUnKnownUnKnownfalsetrue